Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion (Q39161582)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2013

Language	Label	Description	Also known as
English	Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion	scientific article published on September 2013

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion (English)

1 reference

Europe PubMed Central

9 September 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wei Wei

1

1 reference

Europe PubMed Central

9 September 2017

He Huang

2

1 reference

Europe PubMed Central

9 September 2017

Shan Zhao

3

1 reference

Europe PubMed Central

9 September 2017

Wei Liu

4

1 reference

Europe PubMed Central

9 September 2017

Chuan-Xu Liu

5

1 reference

Europe PubMed Central

9 September 2017

Li Chen

6

1 reference

Europe PubMed Central

9 September 2017

Jun-Min Li

7

1 reference

Europe PubMed Central

9 September 2017

Ying-Li Wu

8

1 reference

Europe PubMed Central

9 September 2017

Hua Yan

9

1 reference

Europe PubMed Central

9 September 2017

publication date

1 September 2013

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

18

1 reference

Europe PubMed Central

9 September 2017

9

1 reference

Europe PubMed Central

9 September 2017

1060-1070

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s10495-013-0854-2

0 references

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

JAK-STAT signaling activated by Abl oncogenes

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Antiproliferative sesquiterpene lactones from the roots of Inula helenium

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Identifiers

10.1007/S10495-013-0854-2

1 reference

Europe PubMed Central

9 September 2017

release_rqt2dnnvxrhd7lnu6gvcewko3y

1 reference

https://api.fatcat.wiki/v0/release/rqt2dnnvxrhd7lnu6gvcewko3y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39161582&oldid=2081168471"